Wearable-derived postdischarge mobility as a digital biomarker for 90-day readmission and mortality in metastatic cancer
Supportive Care in Cancer · 2026
DOI: 10.1007/s00520-026-11216-6 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Supportive Care in Cancer, 2026. Verfasst von Orhun Akdogan und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey. orhunakdogan@gmail.com. Hauptthemen laut MEDLINE: Exercise, Neoplasms, Patient Readmission, Wearable Electronic Devices. Die Arbeit nennt 31 Literaturangaben.
Themen: Mobilisation
Abstract (Originalsprache)
Purpose
The postdischarge period after unplanned hospitalization is a vulnerable transition for patients with metastatic cancer, often accompanied by functional decline, symptom burden, psychological distress, early readmission, and death. However, short-term risk assessment during this period still relies largely on episodic clinician-rated measures. We evaluated whether wearable-derived postdischarge step counts are associated with 90-day readmission, mortality, and patient-reported outcomes in patients with metastatic cancer.
Methods
In this prospective, two-center cohort study, adults with stage IV solid tumors discharged after unplanned hospitalization from two tertiary oncology centers were followed for 90 days. Physical activity was assessed using a wrist-worn wearable device, and median daily step count during a prespecified 14-day postdischarge landmark period was used as the main exposure. The primary outcome was unplanned 90-day readmission, and the secondary outcome was 90-day all-cause mortality. Associations with health-related quality of life, sleep quality, anxiety, and depressive symptoms were also evaluated using validated patient-reported outcome measures.
Results
Among 200 evaluable patients, 86 (43.0%) experienced unplanned readmission and 56 (28.0%) died within 90 days. Receiver operating characteristic analysis identified 3013 steps/day as the optimal cutoff for 90-day readmission. Patients with lower postdischarge activity (≤ 3013 steps/day) had substantially higher readmission (73.0% vs 13.0%) and mortality (47.0% vs 9.0%) rates than those with higher activity (both p < 0.001). In multivariable analysis, low step count remained independently associated with readmission (adjusted OR 22.9, 95% CI 9.3–56.6) and mortality (HR 5.46, 95% CI 2.54–11.74). Median daily step count demonstrated strong discrimination for 90-day readmission (AUC 0.86) and mortality (AUC 0.83). Higher postdischarge activity was also associated with better quality of life, better sleep, and lower anxiety and depressive symptom burden. Each 1000-step increase was associated with lower odds of poor sleep quality, clinically significant anxiety, and depressive symptoms.
Conclusion
Wearable-derived postdischarge mobility was strongly associated with short-term clinical outcomes and supportive care–relevant patient-reported outcomes in metastatic cancer. These findings support further evaluation of objective activity monitoring as a scalable, patient-centered approach to postdischarge risk stratification. External validation and prospective interventional studies are needed before wearable-derived mobility measures can be used to guide supportive care strategies.
Trial registration
ClinicalTrials.gov Identifier: NCT06687330.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey. orhunakdogan@gmail.com.
- Department of Medical Oncology, Ankara Etlik City Hospital, Ankara, Turkey.
- Oncoclinicas&Co-Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Brazil.
- Parkview Packnett Family Cancer Institute, Parkview Health System, Fort Wayne, IN, USA.
- Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey.
- Department of Internal Medicine, Gazi University Faculty of Medicine, Ankara, Turkey.
ORCID-Profile: Orhun Akdogan
Zitieren
APA
Akdogan, O., Uyar, G. C., Bergerot, C. D., McCollom, J. W., Tuzcu, T. U., Yesilbas, E., Umunc, F., Baskurt, K., Savas, G., Yildirim, O. A., Gurler, F., Yucel, K. B., Coskun, U., Uner, A., Ozet, A., Yazici, O., Ozdemir, N., Oksuzoglu, B., & Sutcuoglu, O. (2026). Wearable-derived postdischarge mobility as a digital biomarker for 90-day readmission and mortality in metastatic cancer. Supportive Care in Cancer. https://doi.org/10.1007/s00520-026-11216-6
Vancouver
Akdogan O, Uyar GC, Bergerot CD, McCollom JW, Tuzcu TU, Yesilbas E, et al. Wearable-derived postdischarge mobility as a digital biomarker for 90-day readmission and mortality in metastatic cancer. Supportive Care in Cancer. 2026. doi:10.1007/s00520-026-11216-6
BibTeX
@article{Akdogan2026,
author = {Akdogan, Orhun and Uyar, Galip Can and Bergerot, Cristiane Decat and McCollom, Joseph W and Tuzcu, Tuba Ugur and Yesilbas, Enes and Umunc, Fatih and Baskurt, Kadriye and Savas, Gozde and Yildirim, Ozgen Ahmet and Gurler, Fatih and Yucel, Kadriye Bir and Coskun, Ugur and Uner, Aytug and Ozet, Ahmet and Yazici, Ozan and Ozdemir, Nuriye and Oksuzoglu, Berna and Sutcuoglu, Osman},
title = {Wearable-derived postdischarge mobility as a digital biomarker for 90-day readmission and mortality in metastatic cancer},
journal = {Supportive Care in Cancer},
year = {2026},
doi = {10.1007/s00520-026-11216-6}
}
EUVIMED